Analyzing Zimmer Biomet (ZBH) and Exactech (EXAC)
Zimmer Biomet (NYSE: ZBH) and Exactech (NASDAQ:EXAC) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.
Valuation & Earnings
This table compares Zimmer Biomet and Exactech’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Zimmer Biomet||$7.68 billion||3.17||$305.90 million||$3.21||37.43|
Risk & Volatility
Zimmer Biomet has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Exactech has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.
This table compares Zimmer Biomet and Exactech’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations for Zimmer Biomet and Exactech, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Zimmer Biomet presently has a consensus target price of $136.90, suggesting a potential upside of 13.95%. Exactech has a consensus target price of $49.00, suggesting a potential downside of 0.91%. Given Zimmer Biomet’s stronger consensus rating and higher probable upside, equities analysts plainly believe Zimmer Biomet is more favorable than Exactech.
Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 0.8%. Exactech does not pay a dividend. Zimmer Biomet pays out 29.9% of its earnings in the form of a dividend.
Insider & Institutional Ownership
85.9% of Zimmer Biomet shares are held by institutional investors. Comparatively, 66.3% of Exactech shares are held by institutional investors. 1.1% of Zimmer Biomet shares are held by company insiders. Comparatively, 28.3% of Exactech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Zimmer Biomet beats Exactech on 14 of the 17 factors compared between the two stocks.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company’s products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The Company manages its operations through three geographic operating segments: the Americas, consisting principally of the United States and other North, Central and South American markets; EMEA, consisting principally of Europe and the Middle East and African markets, and Asia Pacific, consisting primarily of Japan and other Asian and Pacific markets. The Company’s product category segments include Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic (CMF), and Dental.
Exactech Company Profile
Exactech, Inc. develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines. The Company distributes joint replacement systems, including knee, hip, spine and extremity implant systems, and biologic products and services and bone cement materials used in orthopedic surgery and dental procedures. The Exactech Knee System provides solutions for partial, primary and revision total knee arthroplasty. Its hip solutions address the continuum of hip arthroplasty. It manufactures and distributes various products and services designed for the healing and regeneration of bone and soft tissue, including products, which contain human allograft.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.